A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact

The prognosis of patients with borderline resectable pancreatic cancer with arterial contact (BRPC-A) is extremely poor, and effective preoperative treatment is indispensable. We evaluated the clinical efficacy and safety of neoadjuvant chemotherapy, including gemcitabine, nab-paclitaxel  and S-1 (GAS), for patients with BRPC-A.

Source: European Journal of Cancer - November 12, 2021 Category: Cancer & Oncology Authors: Naru Kondo, Kenichiro Uemura, Takeshi Sudo, Yasushi Hashimoto, Tatsuaki Sumiyoshi, Kenjiro Okada, Shingo Seo, Hiroyuki Otsuka, Yoshiaki Murakami, Shinya Takahashi Tags: Clinical Trial Source Type: research